In September 2025, Dr. Dustin Sulak, the founder of Healer.com and well-known American cannabis expert, presented a webinar exploring how cannabis can help with cancer, wound healing, ALS and Alzheimer’s disease. He summarized five recent studies published between March and July 2025, each exploring promising therapeutic uses for cannabinoids.
Below we present the key points of the webinar.
Dr. Sulak’s review began with a study from Thailand, published in the “Journal of Current Science and Technology”. The research compared outcomes for 98 cancer patients, split between those receiving medical cannabis and those using morphine. Results showed that those who used cannabis lived a little longer, spent fewer days in the hospital, and felt better overall. This means that cannabis might help cancer patients improve the quality of their lives, not just control pain.
A July 2025 animal study examined how daily, low-dose THC injections affected wound healing in older mice. The results were clear: THC treatment over three weeks sped up wound closure and improved healing environments, mimicking those found in younger animals. This means THC might help older people’s bodies repair wounds more quickly by reducing inflammation.
Another highlighted study, from “Biomedicine & Pharmacotherapy”, tested cannabidiolic acid (CBDA) in a mouse model of ALS, a disease that attacks nerve cells. CBDA is an acidic cannabinoid that becomes famous CBD after decarboxylation.
The mice given CBDA had better movement and healthier nerve cells than those treated with usual medicine. This research points to CBDA as a possible new treatment for ALS.
A blind UK trial published in “Age and Ageing” tested nabiximols (a blend of THC and CBD) on Alzheimer’s patients. The treatment was safe, but it improved agitation as much as placebo did. Even so, the trial showed it is possible to do large-scale studies safely in the future.
Finally, a June 2025 study examined whether alpha-pinene, a terpene commonly found in cannabis, could stop THC from hurting memory. Results found no notable effect. But Dr. Sulak emphasized the limitations of testing isolated compounds versus whole-plant cannabis, which contains hundreds of active compounds working together.
Dr. Sulak’s analysis of these five studies demonstrates both the promise and complexities of cannabis as medicine, underscoring the urgency of more rigorous, controlled trials. With the USA and Europe now contributing billions to research budgets, the number of medical cannabis studies are likely to multiply.
A new European powerhouse emerges: Canada's Organigram acquired Germany's Sanity Group for €250 million. Backed by British American Tobacco, this deal reshapes the medical cannabis landscape. Here's what to expect by late 2026.
The 23rd edition of Europe's leading cannabis trade fair will take place on April 17–19, 2026, at its new venue — Bilbao Exhibition Centre in Barakaldo. Find below all the details known about the upcoming Spannabis Festival, from the World Cannabis Conference to the prestigious Champions Cup.
Did you know that Henry Ford’s first car was made from hemp? Or that many great Arab scholars of the Middle Ages — the same ones who gave us modern numerals — used to smoke hashish?
